High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial

Clinical Infectious Diseases

Volumn 47, Issue 1, 2008, Pages 123-130

  Bicanic, Tihana ^a,c   Wood, Robin ^a   Meintjes, Graeme ^a,b   Rebe, Kevin ^a,b   Brouwer, Annemarie ^c,e   Loyse, Angela ^a,c   Bekker, Linda Gail ^a   Jaffar, Shabbar ^d   Harrison, Thomas ^a,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GF Jooste Hospital   (South Africa)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; COTRIMOXAZOLE; FLUCONAZOLE; FLUCYTOSINE; MAGNESIUM; POTASSIUM; AMPHOTERICIN B; ANTIFUNGAL AGENT; CREATININE; HEMOGLOBIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYPTOCOCCAL MENINGITIS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FUNGICIDAL ACTIVITY; HEPATORENAL SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOUTH AFRICA; THROMBOCYTOPENIA; AIDS RELATED COMPLEX; BLOOD; CHEMICALLY INDUCED DISORDER; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; ISOLATION AND PURIFICATION; KIDNEY FAILURE; MICROBIOLOGY; SEX DIFFERENCE; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANEMIA; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; CREATININE; CRYPTOCOCCUS NEOFORMANS; FEMALE; FLUCYTOSINE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; RENAL INSUFFICIENCY; SEX FACTORS; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 46249098244     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/588792     Document Type: Article

References (33)

1. Corbett EL, Churchyard GJ, Charalambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34:1251-8.
2. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031-8.
3. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000; 14:1401-7.
4. Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 1998; 27:698-702.
5. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006; 20:679-97.
6. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326:83-9.
7. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-7.
8. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990; 113:183-7.
9. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337:15-21.
10. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.
11. Saag MS, Graybill RJ, Larsen RA, et al.; Infectious Diseases Society of America. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30:710-8.
12. Robinson PA, Bauer M, Leal MA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28:82-92.
13. de Lalla F, Pellizzer G, Vaglia A, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995; 20:263-6.
14. Western Cape Department of Health. The 2005 Antenatal HIV provincial and area surveys, Western Cape. Cape Town, South Africa: Provincial Government of the Western Cape, 2005.
15. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983; 8:17-42.
16. Joly V, Aubry P, Ndayiragide A, et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996; 23:556-62.
17. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22:315-21.
18. Brandriss MW, Wolff SM, Moores R, Stohlman F Jr. Anemia induced by amphotericin B. JAMA 1964; 189:663-6.
19. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49(Suppl 1):37-41.
20. Gallis HA, Drew RH, PickardWW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-29.
21. Butler WT, Bennett JE, Alling DW, Wertlake PT, Utz JP, Hill GJ. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964; 61:175-87.
22. Hamill RJ, Sobel J, El-Sadr W. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients [abstract 1161]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999.
23. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11:1463-71.
24. Lin AC, Goldwasser E, Bernard EM, Chapman SW. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 1990; 161:348-51.
25. Yeo EJ, Ryu JH, Cho YS, et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 2006; 107:916-23.
26. Brouwer AE, van Kan HJ, Johnson E, et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother 2007; 51:1038-42.
27. Lancaster DJ, Palte S, Ray D. Recombinant human erythropoietin in the treatment of anemia in AIDS patients receiving concomitant amphotericin B and zidovudine. J Acquir Immune Defic Syndr 1993; 6:533-4.
28. Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. Semin Dial 2006; 19:146-51.
29. Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001; 77:769-73.
30. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998; 26:1362-6.
31. Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis 2006; 6:118.
32. Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006; 20:2183-91.
33. Bicanic T, Wood R, Bekker LG, Darder M, Meintjes G, Harrison TS. Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infect Dis 2005; 5:530-1.